Updates from the HUGO Gene Nomenclature Committee (HGNC) relevant to Human Genomics readers.
Featured article: Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites
Metoprolol succinate is a long-acting beta-blocker prescribed for the management of hypertension (HTN) and other cardiovascular diseases. Metabolomics, the study of end-stage metabolites of upstream biologic processes, yield insight into mechanisms of drug effectiveness and safety. Our aim was to determine metabolomic profiles associated with metoprolol effectiveness for the treatment of hypertension.Urinary metoprolol metabolite ratios are indicative of patient CYP2D6 genotypes. Patients taking metoprolol had significantly higher urinary levels of many gut microbiota-dependent metabolites including hydroxyhippuric acid, hippuric acid, and methyluric acid. Urinary metoprolol metabolite profiles of normal metabolizer (NM) patients more closely correlate to ultra-rapid metabolizer (UM) patients than NM patients. Metabolites did not predict either 10% SBP or HR decline.
In summary, in the treatment of HTN, metoprolol therapy appears to alter the gut microbiome and the composition of the microbiome may be an important factor in the effectiveness of antihypertensive drugs. Further work should focus on the stratification of drug effectiveness and gut microbiome composition in order to understand the biologic interactions between these systems.
Human Genomics launched with BioMed Central in July 2012, transferring from its previous publisher Henry Stewart Publications. All back content is now available in the archive.
From the Blog
COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Aims and scope
Human Genomics is a peer-reviewed, open access journal that focuses on the application of genomic analysis in all aspects of human health and disease, as well as genomic analysis of drug efficacy and safety, and comparative genomics.
Guest Editors: George P Patrinos, University of Patras, Greece; Hongyu Zhao, Yale University, USA
Papers are invited which address current issues in human public health genomics, such as genomic surveillance of disease, genetic risk prediction, individual genome interpretation, gene-environment interactions, genetic diversity of vector-borne disease, vaccination and vaccine-based approaches against pathogens data sharing, economic evaluation in genomic medicine, and the role of big data and artificial intelligence on the development of translational tools and services and the overall future of public health.
Submission Deadline: March 2020
- Editorial Board
- Sign up for article alerts and news from this journal
Official journal of
Annual Journal Metrics
54 days first decision for reviewed manuscripts only
41 days to first decision for all manuscripts
110 days from submission to acceptance
27 days from acceptance to publication
432 Altmetric Mentions